Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of OT-82 in Patients With Relapsed or Refractory Lymphoma
Conditions
Interventions
OT-82 Dose Escalation
OT-82 Dose Expansion
Locations
8
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
City of Hope National Medical Center
Duarte, California, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
University of Michigan
Ann Arbor, Michigan, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States
Start Date
July 29, 2019
Primary Completion Date
April 1, 2021
Completion Date
June 1, 2021
Last Updated
October 23, 2020
NCT07249528
NCT04570423
NCT00131014
NCT03050268
NCT07545603
NCT07137494
Lead Sponsor
Oncotartis, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions